LENSAR, Inc. (NASDAQ:LNSR - Get Free Report)'s share price rose 0.9% during mid-day trading on Wednesday . The company traded as high as $8.03 and last traded at $7.64. Approximately 50,678 shares changed hands during trading, an increase of 47% from the average daily volume of 34,456 shares. The stock had previously closed at $7.57.
LENSAR Price Performance
The firm has a market capitalization of $89.55 million, a PE ratio of -5.28 and a beta of 0.70. The firm has a fifty day moving average price of $6.43 and a 200 day moving average price of $5.23.
Institutional Trading of LENSAR
A number of hedge funds have recently bought and sold shares of LNSR. Brandes Investment Partners LP boosted its position in LENSAR by 12.8% during the 2nd quarter. Brandes Investment Partners LP now owns 373,198 shares of the company's stock worth $1,644,000 after acquiring an additional 42,250 shares during the period. Sanctuary Advisors LLC purchased a new stake in shares of LENSAR in the second quarter worth approximately $93,000. Geode Capital Management LLC boosted its holdings in shares of LENSAR by 3.5% during the third quarter. Geode Capital Management LLC now owns 100,431 shares of the company's stock worth $460,000 after purchasing an additional 3,423 shares during the period. Finally, DCF Advisers LLC grew its position in LENSAR by 1.4% during the second quarter. DCF Advisers LLC now owns 241,484 shares of the company's stock valued at $1,087,000 after purchasing an additional 3,250 shares in the last quarter. 40.15% of the stock is owned by hedge funds and other institutional investors.
About LENSAR
(
Get Free Report)
LENSAR, Inc, a commercial-stage medical device company, focuses on designing, developing, and marketing a femtosecond laser system for the treatment of cataracts and the management of pre-existing or surgically induced corneal astigmatism. It offers LENSAR Laser System that incorporates a range of proprietary technologies designed to assist the surgeon in obtaining visual outcomes, efficiency, and reproducibility by providing imaging, procedure planning, design, and precision.
Featured Articles
Before you consider LENSAR, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and LENSAR wasn't on the list.
While LENSAR currently has a "Buy" rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
MarketBeat has just released its list of 20 stocks that Wall Street analysts hate. These companies may appear to have good fundamentals, but top analysts smell something seriously rotten. Are any of these companies lurking around your portfolio? Find out by clicking the link below.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
